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Abstract
Background Platelet inhibition is crucial in reducing both
short- and long-term atherothrombotic risks in patients with
acute coronary syndromes (ACS) managed with percutaneous
coronary intervention (PCI). Based on randomised trials, recent
recommendations in the current guidelines include the endorse-
ment of prasugrel as a first-choice adenosine diphosphate
receptor inhibitor. Yet, there is limited experience with the use
of prasugrel in routine practice.
Methods The Rijnmond Collective Cardiology Research
(CCR) registry is a prospective, observational study that will
follow-up 4000 PCI-treated ACS patients in the larger region
of Rotterdam, the Netherlands. Based on recently implemented
hospital protocols, all patients will receive prasugrel as first-
choice antiplatelet agent, unless contraindicated, in accordance
with European guidelines, and will be followed for up to 1 year
post-discharge for longitudinal assessment of outcomes and
bleeding events. This registry exemplifies a collaborative study
design that employs a regional PCI registry platform and pro-
vides feedback to participating sites regarding their practice
patterns, thereby supporting and promoting improvement of
quality of care.
Conclusion The CCR registry will evaluate the adoption of
prasugrel into routine clinical practice and thus, will provide
important evidence with regard to the benefits and risks of
real-world utilisation of prasugrel as antiplatelet therapy in
PCI-treated ACS patients.
Keywords Acute coronary syndrome . Percutaneous
coronary intervention
Background
Platelet inhibition is crucial for reducing the short- and long-
term risks in patients with acute coronary syndromes (ACS)
[1–3]. Therefore, dual antiplatelet therapy with aspirin and a
thienopyridine for the prevention of thrombotic complications
is recommended in practice guidelines and represents the
standard therapy, particularly in those undergoing percuta-
neous coronary intervention (PCI). Although clopidogrel
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has been the most widely used adenosine diphosphate
(ADP) receptor inhibitor to date, pharmacodynamic inter-
actions and genetic polymorphisms result in significant
variability in the antiplatelet effect of clopidogrel [4–6],
leading to the concern that some patients may be at in-
creased risk for thrombotic events [7–9]. Such limitations
prompted the search for alternative ADP receptor inhibitors
that may provide more potent and more consistent platelet
inhibition.
Prasugrel is a third-generation thienopyridine prodrug that
is more efficiently metabolised to its active metabolite than
clopidogrel and demonstrates a faster onset of action with a
more consistent and greater degree of platelet inhibition [10].
Based on the results of the TRial to assess Improvement
in Therapeutic Outcomes by optimising platelet inhibitioN
with prasugrel—Thrombolysis in Myocardial Infarction
(TRITON-TIMI) 38 [11], prasugrel was approved in Europe
as well as the United States. This study randomised 13,608
patients with moderate-to-high risk ACS scheduled for PCI to
prasugrel (60 mg loading dose, 10 mg maintenance dose) or
clopidogrel (300 mg loading dose, 75 mg maintenance dose).
Prasugrel treatment was associated with a significant 19 %
relative risk reduction (RR) (hazard ratio 0.81, 95 % confi-
dence interval [CI] 0.73–0.90; p <0.001) and a 2.2 % absolute
RR (9.9 % vs. 12.1 %; p <0.001) of the primary efficacy
endpoint (composite of cardiovascular mortality, nonfatal
myocardial infarction, or nonfatal stroke), along with other
ischaemic events compared with clopidogrel. However, the
increased efficacy of prasugrel was counterbalanced by a
clinically significantly increased risk of bleeding, particularly
among patients with a history of stroke or transient ischaemic
attack (TIA), as well as elderly (≥75 years) or underweight
patients (<60 kg) [11].
Based on the results of the TRITON-TIMI 38 trial [11] and
updated guidelines of the European Society of Cardiology
(ESC) for non-ST-segment elevation acute coronary syn-
dromes (NSTE-ACS) [12] and myocardial revascularisation
[13], as well as updated guidelines of the American College of
Cardiology/American Heart Association (ACC/AHA) [14], in
2011, our network instituted prasugrel as first-choice treat-
ment option in patients with ACS undergoing PCI. As this
represents a major change in the treatment of these patients,
we sought to monitor the implementation and clinical out-
comes by means of an observational study. Observational
studies can confirm the generalisability of randomised clinical
trial findings among a broader spectrum of patients, and
allow investigation of comparative effectiveness and safety
of antiplatelet regimens in real-world settings [15]. The
Rijnmond Collective Cardiology Research (CCR) study is a
clinical registry that will provide comprehensive longitudinal
assessment of post-ACS treatment patterns and outcomes in
routine clinical practice. In this article, we describe the design
of the CCR study.
Methods
Study design and population
The CCR study (Dutch Trial Register unique identifier:
NTR3704) is a prospective observational longitudinal regis-
try, which will be conducted at 11 member sites of the CCR
network in the Rijnmond region in the Netherlands. Prospec-
tive sites will include 8 referring hospitals and 3 interventional
centres which are listed in Appendix A. The CCR study will
enrol up to 4000 patients with ACS who are undergoing PCI
during the index hospitalisation and who are treated with an
ADP receptor inhibitor (Fig. 1). Prior to enrolment of the first
patient on 1 August 2011, treatment guidelines of the partic-
ipating network were updated to include prasugrel as a first-
line treatment option for antiplatelet therapy, based on the
available ESC and the ACC/AHA guideline recommenda-
tions at that time. In essence, all patients receive prasugrel,
unless contraindicated. There is no treatment intervention
directed by the protocol of the CCR study. All treatment
decisions are at the discretion of the individual treating phy-
sician in accordance with practice guideline recommendations
and local standards of care and practice. The broad eligibility
criteria are outlined in Table 1.
Ethics
For the purpose of this study patients will not be subjected to
acts or be imposed to any mode of behaviour, otherwise than
their regular treatment. Therefore, according to Dutch law,
written informed consent for a patient to be enrolled in this
study is not required. This study is conducted according to the
Privacy Policy of the Erasmus MC and according to the
Erasmus MC regulations for the appropriate use of data in
patient-oriented research, and is approved by the regional
ethics committee (reference # MEC-2010-417).
Study objectives and endpoints
The primary objective of the CCR study is to monitor clinically
relevant parameters of ACS patients undergoing PCI with a
follow-up of 1 year. The parameters will include baseline
patient characteristics, drug treatments (including timings and
logistic parameters), and clinical outcomes. Other key second-
ary objectives are detailed in Table 2. The primary endpoint of
the study is a composite of all-cause mortality and nonfatal
myocardial infarction. Definitions of the other effectiveness and
safety endpoints are provided in Table 3.
Data collection, data management and event validation
Patient characteristics, clinical features, angiographic and pro-
cedural details, and in-hospital outcomes are abstracted from
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the medical chart per routine and entered into a secure web-
based and centralised database by enrolling site personnel.
Data quality is maintained by various quality measures, includ-
ing integrated data check systems with plausibility thresholds.
All collected data elements are subject to additional data checks
with queries to enrolling sites, thereby maximising complete-
ness of data and quality. After the index hospitalisation, patients
are routinely followed up at 1 month (±2 week) and 12 months
(+2 months) at the outpatient clinics of the enrolling sites, after
which longitudinal information on patient treatment, effective-
ness and safety outcomes is collected and entered into the central
database. Independent data monitoring on-site at each enrolling
centre is conducted monthly with feedback and training of site
data managers.
When study endpoints are suspected, this will be entered
into the central database by site personnel. Hereafter, addi-
tional documents, including relevant hospital discharge sum-
maries, procedural reports, or angiographic films, will be
obtained for event validation by an independent clinical end-
point committee.
Sample size determination
Precision in measurement and estimation corresponds to the
reduction of random error; it can be improved by increasing
the size of the study. Approximately 4000 patients will be
enrolled in the CCR study. Previous real-world data in our
region showed an overall 1-year rate of at least 8.0 % for the
primary combined endpoint (composite of all-cause mortality
and myocardial infarction) in PCI-treated ST-segment eleva-
tion myocardial infarction (STEMI) patients. This corre-
sponds with a 95 % CI of 8.0±0.8 % for a population of
4000 patients and, thus, provides a statistically precise esti-
mate in the current study. In NSTE-ACS patients undergoing
PCI, we expect an overall 1-year rate of 5.0 %, corresponding
with a 95 % CI extending from 5.0 %±0.7 % in a dataset
containing 4000 patients. For subgroup analyses including
1000 observations, the 95 % CI will be 5.0 %±1.4 %.
Fig. 1 Longitudinal study design of the CCR study. *Clopidogrel
600 mg loading dose and 75 mg/daily maintenance dose when prasugrel
is contraindicated. ACS indicates acute coronary syndrome; CABG cor-
onary artery bypass grafting; CV cardiovascular; LD loading dose;
MACE major adverse cardiac events; MD maintenance dose; MI
myocardial infarction; PCI percutaneous coronary intervention; ST stent
thrombosis; and TVR target vessel revascularisation
Table 1 Eligibility criteria
Eligibility criteria
Inclusion criteria
•Has been diagnosed with NSTE-ACS or STEMI and treated with PCI
during index hospitalisation
• Age ≥18 years
Exclusion criteria
• Intolerance or allergy for aspirin, clopidogrel or prasugrel
NSTE-ACS indicates non-ST-segment elevation acute coronary
syndrome; PCI, percutaneous coronary intervention; and STEMI,
ST-segment elevation myocardial infarction
Table 2 Study objectives
Study objectives
Primary objective
•Monitor clinically relevant parameters of PCI-treated ACS patients up
to 12 months
Key secondary objectives
•Compare prasugrel to clopidogrel with regard to the occurrence of the
primary combined endpoint of all-cause mortality and MI at 1 and
12 months
•Compare prasugrel to clopidogrel with regard to the occurrence of the
following secondary endpoints at 1 and 12 months: all-cause
mortality, cardiovascular mortality, MI, stroke, TVR, stent
thrombosis, MACE (composite of cardiovascular mortality, MI, and
TVR)
• Compare prasugrel to clopidogrel with regard to the occurrence of
non-CABG-related TIMI bleeding endpoints at 1 and 12 months
•Compare prasugrel to clopidogrel with regard to the occurrence of the
primary combined endpoint of all-cause mortality and MI, and
bleeding endpoints at 1 and 12 months in the following subgroups:
the elderly (≥75 years), underweight patients (<60 kg)
ACS indicates acute coronary syndrome; CABG, coronary artery bypass
grafting; MACE, major adverse cardiac events; MI, myocardial infarc-
tion; PCI, percutaneous coronary intervention; TIMI, Thrombolysis In
Myocardial Infarction; and TVR, target vessel revascularisation
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Statistical analysis
Continuous variables will be summarised as mean ± standard
deviation or median with interquartile range, depending on
normal distribution and will be compared using the Student
t -test or Mann–Whitney U-test as appropriate. Categorical
variables will be summarised as proportions and compared
using the chi-square test. Whenever necessary, multivariable
analyses, such as binary logistic regression analyses, will be
performed. Differences between groups in time-to-event end-
points will be assessed with the log-rank test. Survival prob-
abilities will be displayed and calculated using Kaplan-Meier
methodology. Hazard ratios between groups will be calculated
using Cox proportional hazard model. Two-sided P-values
<0.05 will be considered statistically significant.
Study cohorts will be determined based on the ADP recep-
tor inhibitor received at the time of the index PCI. For patients
who discontinue or change to a different ADP receptor inhib-
itor, events that occur within 7 days of medication switch or
discontinuation will be counted toward the ADP receptor
inhibitor at the time of index PCI. Events that occur >7 days
after the medication switch or discontinuation will be
censored in the primary analysis.
For determination of real-world comparative benefits of
prasugrel relative to clopidogrel, as outlined in the secondary
objectives (Table 2), we will use existing outcome data in the
Erasmus MC data repository of historical clopidogrel-treated
patients.
Study organisation
The CCR study is supported by Eli-Lilly Nederland B.V. and
Daiichi Sankyo Nederland B.V. Other than providing financial
support, they are not involved in the study design, study
management, or data interpretation. The CCR steering com-
mittee, composed of experienced clinical investigators in
interventional cardiology (Appendix B), is solely responsible
for the design and conduct of this study, all study analyses,
and the drafting and editing of this and forthcoming manu-
scripts. The steering committee will have full access to the
final study data.
An independent clinical endpoint committee will adjudi-
cate efficacy endpoint events as well as bleeding events. As
the CCR registry is an observational study, there are no
provisions for a data safety monitoring board. Enrolling sites
and treating physicians will follow all applicable Dutch laws
and regulations for reporting events to authorities and/or local
market authorisation holder.
Timeline
The first patient was enrolled on 1 August 2011. The antici-
pated duration of enrolment is approximately 18 months or
until the intended number of 4000 patients is recruited.
Discussion
The CCR registry is a prospective, multicentre, longitudinal,
observational study designed to assess the in-hospital and
1-year care patterns and outcomes in ACS patients treated
with PCI and antiplatelet therapy. As our network instituted
prasugrel as the first-line treatment option in patients with
ACS undergoing PCI, this study provides an ideal means of
evaluating the adoption of this novel agent in routine practice.
Table 3 Study endpoints and definitions
Study endpoints
Primary endpoint Composite of all-cause mortality and nonfatal MI
Secondary endpoints All-cause mortality, cardiovascular mortality,






Death due to any reason
Cardiovascular
mortality
Death due to a proven cardiovascular cause or any
death not clearly attributable to a non-
cardiovascular cause
Nonfatal MI Diagnosis of NSTEMI or STEMI on
hospitalisation report, typically defined as
ischaemic symptoms, and 1 of the following:
1) cardiac biomarkers with at least 1 of the
values greater than the local laboratory
reference range, 2) new ECG changes
indicative of ischaemia (ST-Tchanges, new left
bundle branch block, new pathological Q
waves), 3) imaging evidence of loss of viable
myocardium or regional wall motion
abnormality
Stroke Rapid onset of new, persistent, neurological
deficit lasting at least 24 h or leading to death
before 24 h
TVR PCI performed at study treatment site since
previous visit or contact
Stent thrombosis Defined per ARC criteria [23] as definite or
probable ST. Timing of ST is classified as acute
(<24 h), subacute (24 h to 30 days), late
(1 month to 1 year) and very late (>1 year)





Defined per TIMI haemorrhage criteria [24] as
major, minor and minimal bleeding not related
to CABG
ARC indicates Academic Research Consortium and ST, stent thrombosis.
All other abbreviations can be found in Table 1 and 2
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Recommendations from the ESC guidelines stress the impor-
tance of the development of regional and/or national programs
to measure performance indicators systematically that can
provide feedback to individual hospitals [12]. In addition,
the participation in standardised quality-of-care data registry
for tracking and measuring outcomes and complications,
among other goals, is encouraged in the ACC/AHAguidelines
[14]. Not only will the CCR study allow the comparison of
prasugrel with historical clopidogrel-treated patients with
respect to clinical outcomes, and thereby confirm the
generalisability of randomised findings among a broader
spectrum of patients, but also important evidence will be
provided concerning several unanswered questions with
regard to the use of prasugrel in routine practice, which
are discussed below.
Pretreatment with prasugrel
Based on current guidelines, the use of prasugrel in NSTE-
ACS patients should be restricted to patients with known
coronary anatomy [12]. On the other hand, these guidelines
also recommend the administration of a thienopyridine as
soon as possible when ACS is suspected [12] and state that
it is not desirable to withhold optimal medical therapy until
intervention. Indeed, the advantage of early administration of
a thienopyridine loading dose for patients with unknown
coronary anatomy prior to diagnostic angiography would be
to achieve higher inhibition of platelet aggregation and thus
prevent recurrent atherothrombotic events in patients likely to
undergo PCI. Therefore, in our network, prasugrel is already
initiated upstream in the ambulance during transportation for
primary PCI in STEMI patients. Randomised clinical trials in
which the effect of thienopyridine pretreatment (timings) in
ACS is being investigated are ongoing. The ACCOAST trial
will compare two prasugrel loading dose schedules in patients
with NSTEMI who are scheduled for coronary angiography/
PCI [16]. The effect of an early pretreatment (30 mg loading
dose after diagnosis followed by coronary angiography with
an additional dose of 30 mg given at the time of PCI) on
clinical outcome will be compared with non-pretreatment
(standard 60 mg loading dose at the time of PCI) [16]. The
ATLANTIC trial investigates prehospital vs. in-hospital use of
ticagrelor in patients with STEMI referred for primary PCI
(ClinicalTrials.gov identifier: NCT01347580). In this regard,
the CCR study will provide real-world data concerning the
timing of pretreatment with prasugrel and outcomes in pa-
tients with ACS. Patients will receive a 60 mg loading dose of
prasugrel before arrival at the cathlab either prehospital
(ambulance), in the referring hospital or in-hospital (emergency
room or coronary care unit). Our observations will extend the
findings from randomised trials and will provide important
evidence from real-world practice.
Bleeding risk and subgroups
As expected, the improved efficacy of prasugrel in the
TRITON-TIMI 38 trial was associated with higher rates of
bleeding [11]. Particularly, the elderly (≥75 years) and under-
weight patients (<60 kg) tended to bleed more frequently with
the conventional dose (10mg) of prasugrel.While in the elderly
and underweight patients the net clinical benefit (primary end-
point plus major haemorrhage) of prasugrel was comparable
with clopidogrel, patients with a history of stroke or TIAwere at
higher risk for bleeding with unfavourable outcome [11]. Based
on these findings, prasugrel is contraindicated in patients with
previous stroke or TIA. However, despite the lack of clinical
outcome data as well as limited pharmacodynamic data [17], a
lower maintenance dose (5 mg instead of 10 mg) is recom-
mended by the European Medicines Agency for elderly and/or
underweight patients. Whether the proposed reduction of the
maintenance dose of prasugrel to 5 mg is efficacious and safe
will also be investigated in the CCR study.
Triple therapy
The management of patients on oral anticoagulation (e.g. for
atrial fibrillation, mechanical heart valves) requiring antiplatelet
therapy after PCI remains another challenging issue. Since there
are limited data available, both the ESC and theACC/AHAhave
marginally included recommendations in the guidelines regard-
ing triple therapy. Different clinical scores concerning thrombot-
ic (CHA2DS2-VASC score) [18, 19] and bleeding (HAS-BLED
score) [20] risk may provide additional guidance in therapeutic
decisions in such patients. Importantly, however, the CCR study
will provide real-world data regarding treatment patterns and
bleeding outcomes in patients prone to triple therapy.
Ticagrelor
Along with prasugrel, the use of ticagrelor as antiplatelet
therapy in ACS patients undergoing PCI is also recommended
in current guidelines [12, 13, 21]. Ticagrelor, a non-
thienopyridine ADP receptor inhibitor causing reversible in-
hibition of platelet aggregation, has been tested against
clopidogrel in the Study of Platelet Inhibition and Patient
Outcomes and proved beneficial with respect to a combined
clinical outcome including mortality [22]. The rate of severe
non-CABG-related bleeding [22] was similar to that of
prasugrel in the TRITON-TIMI 38 trial [11], whereas
CABG-related bleeding was lower than for clopidogrel [22].
In patients with STEMI, ticagrelor lost its statistically signif-
icant superiority over clopidogrel with respect to the primary
combined endpoint (10.8 % vs. 9.4 %; 13 % relative RR; p =
0.07) [23], whereas a pronounced benefit was demonstrated in
a STEMI population when treated with prasugrel (12.4 % vs
10.0 %; 21 % relative RR; p =0.02) [24]. However, as there
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are no head-to-head comparison studies of prasugrel and
ticagrelor, potential differences between the two agents remain
hypothetical.
Conclusion
The CCR registry is a prospective, longitudinal, observational
study designed to evaluate the adoption of prasugrel into routine
clinical practice. This study will provide important evidence
regarding the benefits and risks of the use of prasugrel as initial
antiplatelet treatment strategy in patients with ACS undergoing
PCI. Along with providing comparative effectiveness with
clopidogrel-treated patients, and thereby extending randomised
findings across a broad array of patient types and practice
settings, crucial real-world data, including pretreatment, bleed-
ing risk in certain subgroups, and triple therapy will be gathered
in the near future with regard to the use of prasugrel in real-
world situations. Finally, the CCR study is in accordance with
guidelines stressing the importance of quality improvement and
performance assessment in the management of ACS patients.
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